ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (SPRY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
spry · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for ARS Pharmaceuticals, Inc. (SPRY) measures how much investors pay for each dollar of the company's trailing earnings. SPRY's current PE ratio of N/A is calculated by dividing its stock price of $8.99 by its TTM earnings per share of -$1.99.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ARS Pharmaceuticals, Inc.You SPRY | $893M | N/A | — | -$1.99 |
 Arbutus Biopharma Corporation ABUS | $838M | N/A | — | -$0.17 |
 GH Research PLC GHRS | $1.4B | N/A | — | -$0.79 |
 Kura Oncology, Inc. KURA | $760M | N/A | — | -$3.18 |
 LENZ Therapeutics, Inc. LENZ | $211M | N/A | — | -$2.85 |
 Nanobiotix S.A. NBTX | $1.8B | N/A | — | -$0.50 |
 ProKidney Corp. PROK | $575M | N/A | — | -$0.52 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.74 | — | |
2024-12-31 FY2024 | 127.87x | $0.08 | — | |
2023-12-31 FY2023 | — | $-0.57 | — | |
2022-12-31 FY2022 | — | $-0.87 | — | |
2021-12-31 FY2021 | — | $-0.70 | — | |
2020-12-31 FY2020 | — | $-0.03 | — | |
2019-12-31 FY2019 | — | $-0.72 | — | |
2018-12-31 FY2018 | — | $-0.53 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ARS Pharmaceuticals, Inc. (SPRY) measures how much investors pay for each dollar of the company's trailing earnings. SPRY's current PE ratio of N/A is calculated by dividing its stock price of $8.99 by its TTM earnings per share of -$1.99.
Frequently asked questions
SPRY pe ratio · 6 questionsSPRY's current PE ratio is N/A as of 2026-06-09, based on a stock price of $8.99 and TTM EPS of -$1.99. Data sourced from Financial Modeling Prep via SPRY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ARS Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09